Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors

Introduction: A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and survival have been known. Methods: We performed a retrospective analysis of outcomes in patients with metastatic melanoma trea...

Full description

Bibliographic Details
Published in:	Biomedicines
Main Authors:	Tanja Mesti, Cvetka Grašič Kuhar, Janja Ocvirk
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Subjects:	immune checkpoint inhibitors metastatic melanoma predictive and prognostic biomarkers immune-related adverse events immune-inflammation parameters
Online Access:	https://www.mdpi.com/2227-9059/11/3/749

Similar Items

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
by: Ana Erman, et al.
Published: (2023-07-01)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
by: Ivana De Risi, et al.
Published: (2022-09-01)

Reactivaion of immune-related colitis during targeted therapy in a patient with metastatic cutaneous melanoma
by: E. A. Degtiareva, et al.
Published: (2022-11-01)

Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma
by: Maximilian Haist, et al.
Published: (2022-03-01)

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
by: Christopher C. Frohne, et al.
Published: (2019-01-01)

Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events
by: Elias A. T. Koch, et al.
Published: (2024-06-01)

Supervised clustering of peripheral immune cells associated with clinical response to checkpoint inhibitor therapy in patients with advanced melanoma
by: A.H. Kverneland, et al.
Published: (2023-12-01)

Early-time-point 18F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy
by: Hribernik Nezka, et al.
Published: (2025-02-01)

Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
by: Panagiotis T. Diamantopoulos, et al.
Published: (2025-04-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Progression of vertebral fractures in metastatic melanoma and non-small cell lung cancer patients given immune checkpoint inhibitors
by: Marco Meazza Prina, et al.
Published: (2024-12-01)

Spontaneous haematoma: A unique immune-related adverse event alongside other cutaneous reactions in a patient treated with pembrolizumab for metastatic melanoma
by: Dalila Malek, et al.
Published: (2024-12-01)

Immune checkpoint inhibitor outcomes and prognostic factors in gynecologic tract melanoma: a single-center analysis
by: Jianzhang Wang, et al.
Published: (2025-04-01)

The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01)

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments
by: Xueyan Wang, et al.
Published: (2022-10-01)

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

Treatment of Refractory Checkpoint-Inhibitor-Induced Hepatitis with Tacrolimus: A Case and Review of the Literature
by: Ruben De Wilde, et al.
Published: (2023-06-01)

Hepatobiliary complications of immune checkpoint inhibitors in cancer
by: Donna Zhuang, et al.
Published: (2024-07-01)

Clearance of plasma cell free DNA in metastatic uveal melanoma with radiographic response to immune checkpoint inhibitors
by: Jasmine H. Francis, et al.
Published: (2024-06-01)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
by: Karam Khaddour, et al.
Published: (2021-06-01)

Application of Immune Checkpoint Inhibitors in Cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs
by: Alisa Lepper, et al.
Published: (2023-12-01)

Durable complete response in a patient with BRAF-mutated advanced melanoma with ocular and skin toxicities from BRAF/MEK targeted therapy after immune checkpoint inhibitor treatment: a case report
by: Carlotta Bertolina, et al.
Published: (2025-06-01)

Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)
by: L. Yu. Vladimirova, et al.
Published: (2021-08-01)

Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma
by: Adi Kartolo, et al.
Published: (2022-03-01)

Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
by: Jingjing Su, et al.
Published: (2024-01-01)

Adverse reactions of immune checkpoint inhibitors
by: E. R. Zagidullina, et al.
Published: (2025-06-01)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
by: Lavinia Spain, et al.
Published: (2019-06-01)

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook
by: Linh Chi Tran, et al.
Published: (2023-10-01)

IVC thrombectomy and atrial tumor removal with radical nephrectomy and adrenalectomy for metastatic melanoma with immune checkpoint inhibitor therapy: A case report and literature review
by: Michael Raver, et al.
Published: (2024-07-01)

Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma
by: Charlotte Nübel, et al.
Published: (2023-11-01)

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
by: Parneet K. Cheema, et al.
Published: (2024-10-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Autoimmune Encephalitis following Checkpoint Inhibitor Therapy in a Patient with Metastatic Melanoma in Complete Remission
by: Giuseppe Civardi, et al.
Published: (2024-04-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Hepatotoxicity induced by immune checkpoint inhibitors
by: Flaviu Muresan, et al.
Published: (2024-10-01)

Immunometabolism signature derived from on-treatment tumor specimens predicts immune checkpoint blockade response in metastatic melanoma
by: Shuzhao Chen, et al.
Published: (2025-07-01)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
by: Chune Yu, et al.
Published: (2019-05-01)

Case Report: Immune checkpoint inhibitor-induced myositis without elevated creatine kinase
by: Klajdi Begaj, et al.
Published: (2025-06-01)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
by: Justin Tong, et al.
Published: (2022-10-01)